Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
BioSimilars Market Ripe for Expansion
Can Innovation in Drug Design Stem the Rising Tide?
- Therapeutic proteins are a $60-billion industry. However, since 40% have lost their patent protection and more are soon to follow, producing biosimilars is now arousing great interest from generic manufacturers everywhere, warned Beatrice Muzard, equity analyst for pharmaceuticals at Ixis Corporate Solutions (www.cdcixis-cm.com), during the recent “BioSquare” conference held ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.